J.S. Skotnicki

Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3 S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis

Yuhua Zhang, Jun Xu, Jeremy I. Levin et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 91 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

The discovery of anthranilic acid-Based MMP inhibitors. Part 2: SAR of the 5-position and P11 groups

Jeremy I. Levin, J. Chen, Mingyang Du et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 75 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +6

Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1′ group

Jeremy I. Levin, J.M Chen, Mingyang Du et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 75 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +6

Identification of potent and selective MMP-13 inhibitors

Junjun Wu, Thomas S. Rush, Rajeev Hotchandani et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 70 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme

Yuhua Zhang, Martin Hegen, Jun Xu et al. · International Immunopharmacology · 2004 · 55 citations

Life Sciences, Medicinal Chemistry, Pharmacology +11